00:28:39 EDT Thu 03 Jul 2025
Enter Symbol
or Name
USA
CA



News for U:IBIO from 2024-07-04 to 2025-07-03 - 19 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-06-24 07:00U:IBIONews ReleaseiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
2025-06-23 16:15U:IBIONews ReleaseiBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
2025-06-16 07:00U:IBIONews ReleaseiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
2025-05-05 08:00U:IBIONews ReleaseiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
2025-05-02 08:00U:IBIONews ReleaseiBio Reports Fiscal Third Quarter 2025 Financial Results
2025-04-29 13:44U:IBIONews ReleaseiBio Raises $6.2 Million Through Warrant Inducement Transaction
2025-04-22 08:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
2025-04-07 07:00U:IBIONews ReleaseiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
2025-02-19 16:05U:IBIONews ReleaseiBio to Begin Trading on the Nasdaq Stock Exchange
2025-02-10 16:05U:IBIONews ReleaseiBio Reports Fiscal Second Quarter 2025 Financial Results
2025-01-13 07:00U:IBIONews ReleaseiBio Announces New Investments from Board Members and Officers
2025-01-07 07:00U:IBIONews ReleaseiBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
2025-01-02 07:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
2024-11-25 08:00U:IBIONews ReleaseiBio Strengthens Board with Appointment of Two New Independent Directors
2024-11-12 16:05U:IBIONews ReleaseiBio Reports Fiscal First Quarter 2025 Financial Results
2024-10-10 08:00U:IBIONews ReleaseiBio and AstralBio Provide Update on Myostatin Program for Obesity
2024-09-20 16:05U:IBIONews ReleaseiBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
2024-09-03 07:00U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2024-08-12 16:30U:IBIONews ReleaseiBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development